TVAX Biomedical   Report issue

For profit Phase 2
Founded: Lenexa KS United States (2004)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2010
NCT01081223
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (3)

aldesleukin (proleukin) (1 trial)

tvi-brain-1 (2 trials)

white blood cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Astrocytoma (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3